Key Highlights
● ABT closed at $99.71 on 9 October 2026, and the $118.88 consensus target implies upside of roughly 19.2%.
● The consensus draws on 28 analysts, with targets from $92 to $135, while a second data set shows a $120.72 average.
● Market data counts three Strong Buy, 21 Buy and four Hold ratings with no Sell.
● Barclays initiated at Overweight with a $120 target on 7 October, and Redburn upgraded to Buy on 2 October with a $127 target.
Abbott Laboratories (NYSE:ABT), the diversified healthcare group, is a member of the S&P 500. Its shares closed at $99.71 on Friday 9 October 2026, with the consensus analyst target implying upside of roughly 19%.
What Is the Latest Analyst Price Target?
Market data reports a consensus price target of $118.88 for Abbott, based on 28 analysts who rated the stock in the past 12 months. The range runs from a low of $92.00 to a high of $135.00. Against the $99.71 close, the consensus implies upside of roughly 19.2%.
The second data set, which also counts 28 analysts, shows a slightly higher average of $120.72 and a median of $120.00, with targets between $103 and $135. Its data were last updated on 7 October, so they predate the Friday close. The difference between the two data sets is modest.
Recent named targets are broadly consistent with these figures. Eleven broker targets published since July average about $123, so the consensus does not appear to be distorted by stale forecasts.
What Are Wall Street Analysts Saying?
Sentiment is firmly positive. Market data lists three Strong Buy, 21 Buy and four Hold ratings with no Sells, giving a Moderate Buy consensus. The second data set describes the consensus as Strong Buy, with 19 Strong Buy, five Buy and four Hold ratings.
Several brokers have acted in the past few weeks. Barclays, through analyst Matt Miksic, initiated coverage on 7 October with an Overweight rating and a $120 target. On 2 October, Rothschild & Co Redburn upgraded the shares from Neutral to Buy and lifted its target from $119 to $127. TD Cowen reiterated a Buy rating with a $135 target on 8 September, and Wolfe Research upgraded to Outperform with a $130 target on 13 August. After the second-quarter results, JPMorgan raised its target from $110 to $120 and BTIG from $131 to $134 on 17 July, while UBS trimmed its target from $135 to $125 on 28 July.
What Could Help the Stock Reach the Price Target?
The most visible support is operating momentum. In the second quarter of 2026 Abbott reported earnings per share of $1.31 against a consensus estimate of $1.28, and revenue of $12.59 billion, up 13.0% on a year earlier. Continued growth at that kind of pace, if achieved, would give analysts a basis for their higher targets.
The recent run of new coverage and upgrades may also help sentiment. Fresh Buy-rated views from Barclays and Redburn suggest that some institutions see the shares as undervalued relative to their forecasts.
What Could Prevent the Stock Reaching the Target?
The shares trade almost 20% below the consensus target, which indicates that the market is not fully accepting the analyst view. Reasons could include sector-wide concerns about healthcare spending, currency effects or competition in medical devices and diagnostics.
Analyst forecasts can also change. UBS lowered its target in July, and the lowest market data target of $92.00 shows that not every forecaster sees large gains.
What Should Investors Watch Next?
In the meantime, watch for further broker initiations or revisions, any update to company guidance and sector news affecting healthcare valuations.
Abbott's Gap to Target Rests on Second-Quarter Momentum and Fresh Coverage
Abbott closed at $99.71 on 9 October 2026, while the $118.88 consensus target implies upside of about 19% and the second data set's $120.72 average points slightly higher. Ratings are overwhelmingly Buy-oriented, with no Sell in market data, and the case leans on second-quarter earnings of $1.31 per share and 13.0% revenue growth plus new Overweight and Buy views from Barclays and Redburn. UBS's July cut to $125 and a low target of $92 show the range is not one-sided.






Please wait processing your request...